GSK, Teva Press High Court To Hear Lamictal Case
GlaxoSmithKline and Teva pressed the U.S. Supreme Court on Monday to review a Third Circuit ruling that found they could face pay-for-delay claims involving the anticonvulsant Lamictal, arguing the decision "eviscerates"...To view the full article, register now.
Already a subscriber? Click here to view full article